Excellent response of basal cell carcinomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream

Br J Dermatol. 2003 Oct;149(4):858-61. doi: 10.1046/j.1365-2133.2003.05613.x.

Abstract

Xeroderma pigmentosum (XP) is an autosomal recessive disease in which patients have a 1000-fold increased risk of developing cutaneous neoplasms. Management of patients with XP is a difficult therapeutic challenge as they usually present with many cutaneous malignancies and continue to form skin tumours at a high rate. We describe a 19-year-old woman with XP who had been previously treated with many different therapeutic approaches. She had an excellent clinical response of her multiple small pigmented basal cell carcinomas and pigmentary changes using imiquimod 5% cream with only minor side-effects.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aminoquinolines / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Basal Cell / etiology
  • Carcinoma, Basal Cell / pathology
  • Female
  • Humans
  • Imiquimod
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / etiology
  • Skin Neoplasms / pathology
  • Xeroderma Pigmentosum / complications
  • Xeroderma Pigmentosum / drug therapy*
  • Xeroderma Pigmentosum / pathology

Substances

  • Aminoquinolines
  • Antineoplastic Agents
  • Imiquimod